First evaluation of the safety, pharmacokinetics and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor Xia. Science ShareTwitterFacebookXingLinkedin anticoagulantfactor XIhemostasisphase 1thrombosis You May Also Like Science 30. Januar 2023 Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. Science 30. Januar 2023 Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Science 30. Januar 2023 The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.
